Antigen processing in vivo and the elicitation of primary CTL responses
about
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunizationHepatitis C virus and ethanol alter antigen presentation in liver cellsA vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II moleculesExploiting cross-priming to generate protective CD8 T-cell immunity rapidly.The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.DNA and RNA-based vaccines: principles, progress and prospects.DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum.The promise of nucleic acid vaccines.CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection.An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope.mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.Modulating numbers and phenotype of CD8+ T cells in secondary immune responses.CD69 does not affect the extent of T cell primingPeptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation.Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen.Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice.The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cellsA gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitopePopulation dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo.Virally activated CD8 T cells home to Mycobacterium bovis BCG-induced granulomas but enhance antimycobacterial protection only in immunodeficient mice.The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Developing recombinant and synthetic vaccines for the treatment of melanoma.The new vaccines: building viruses that elicit antitumor immunity.IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigenEffective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infectionT cells compete for access to antigen-bearing antigen-presenting cells.Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing.CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligandVaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
P2860
Q24648492-489985A8-F5F5-431B-A89B-A1F8CB7E3557Q24670153-4F2359FA-D016-49CE-8BEB-2B1B8C8654DBQ27488237-B11815A1-2760-417D-97BA-4F3F64558320Q28751663-0C8DCB2F-7F5F-41C3-B7D3-EA85E4CA05DFQ30391225-9B68D60D-BF28-406C-809C-22989366ACD3Q30444065-409B1302-483D-4324-B5B0-0F03F2573745Q30452613-D13A4253-EC72-4156-9173-107DE8FD6B6EQ33532640-D2813FB8-EA91-4E6F-881E-51C8092D9C3BQ33783789-57C428EE-96D9-40C6-8FF5-2766A262E7AFQ33784641-CE766A48-BF92-483C-9D31-39ACDA681100Q33791476-6BC1EC85-7C75-441B-A151-99BF5CBF17ADQ33837119-293A33B7-D6F2-4F61-B533-148EDD906F83Q33943864-0E77DD09-E6E8-4F5B-8981-E6995EFF5778Q34000642-4473ABFA-AF84-4A6D-838A-22B4A19BCA66Q34069951-19242D9A-315C-457B-B9DF-7C05A3F6BDDDQ34317937-0824075B-D1C3-4F26-A3F3-E5F921AC2F46Q34357154-5F398CAF-2E38-48B3-AF7B-FA4499FEF0E7Q34465300-FE52E4D1-865E-48B4-B7AF-5778EADDF86FQ34482124-54126BD0-E6D4-46A2-AD44-CBDCCF36A055Q34694971-9453F7DE-32EB-4923-967F-A65901ECCB22Q35070693-47336BAB-EC52-426C-B6AA-B2EFB2699C1FQ35079839-C1826D13-4595-49F9-906F-42EFE4C2E3D7Q35204687-C223ED13-856C-4CE7-AFB1-4C4E7F803E14Q35601591-29914509-9B55-49AB-9FC3-8E36B81F71F8Q35685624-5663DD30-B6E5-4E0E-82DA-57AE3E0BFBBAQ35689479-D28D73A9-E5AF-4465-A5C2-282CC6EB3FBAQ35867988-B9C71467-F27F-4594-9C15-6DD0D7A437ECQ35946196-862444B1-28A9-4D71-B193-04859C6CEFB8Q35946203-B3E9831F-4DBF-4E6D-846B-F3DAF07A97A3Q35950374-6594754D-C729-406B-834E-4D5B6A77836BQ36167792-578489F4-8158-4FBD-A9D9-AF9E6BEA1396Q36172572-DD7E1823-7599-4379-8B8C-75C4DE68998CQ36229655-1217A844-6B8F-4F11-BFA6-5D9AD627717EQ36366108-DD1D2A78-D259-407A-9952-699CB5C52CF9Q36369054-D508FCED-85A5-4D58-B673-70E045BD0D34Q36376071-9E62C886-9F14-4923-BB9D-548C102B177AQ36380657-65224345-2EED-4A21-AF2F-8FB9AA43098DQ36399276-041E2EA2-74DB-4749-BCA0-8EAA3076EE21Q36401461-31D701FF-64C6-45BC-A172-1884E9D7F511Q36456749-102B2383-07AA-44FA-9218-647D61FDA763
P2860
Antigen processing in vivo and the elicitation of primary CTL responses
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Antigen processing in vivo and the elicitation of primary CTL responses
@ast
Antigen processing in vivo and the elicitation of primary CTL responses
@en
Antigen processing in vivo and the elicitation of primary CTL responses
@nl
type
label
Antigen processing in vivo and the elicitation of primary CTL responses
@ast
Antigen processing in vivo and the elicitation of primary CTL responses
@en
Antigen processing in vivo and the elicitation of primary CTL responses
@nl
prefLabel
Antigen processing in vivo and the elicitation of primary CTL responses
@ast
Antigen processing in vivo and the elicitation of primary CTL responses
@en
Antigen processing in vivo and the elicitation of primary CTL responses
@nl
P2093
P2860
P3181
P1476
Antigen processing in vivo and the elicitation of primary CTL responses
@en
P2093
B J McCabe
J R Bennink
J W Yewdell
K R Irvine
L C Eisenlohr
N P Restifo
R W Anderson
S A Rosenberg
P2860
P304
P3181
P407
P577
1995-05-01T00:00:00Z